Variable | Relative risk compared with nonpregnant women without the risk factor | Absolute risk |
Nonpregnant, not taking hormones | 1.0 | VTE: 1 to 5/10,000 woman-years[1] |
Pregnancy | 4.29 (95% CI 3.49-5.22; p<0.001) compared with nonpregnant women[4] | VTE: 5 to 20/10,000 woman-years[1] PE: 1/10,000 woman-years |
Postpartum | 4.29 (95% CI 3.49-5.22; p<0.001) compared with nonpregnant women[4] | VTE: 40 to 65/10,000 woman-years[1] PE: 16 per 10,000 woman-years |
Progestin type | RR of VTE:[2,3] | |
Non-use versus first-generation (norethindrone COC) users: 3.2 (95% CI 2.0-5.1) | ||
Non-use versus second-generation (levonorgestrel COC) users: 2.8 (95% CI 2.0-4.1) | ||
Non-use versus third-generation (desogestrel COC) users: 3.8 (95% CI 2.7-5.4) | ||
Second versus first generation: 0.9 (95% CI 0.6-1.4) | ||
Third versus first generation: 1.2 (95% CI 0.8-1.9) | ||
Third versus second generation: 1.3 (95% CI 1.0-1.8) | ||
Estrogen dose | 20 mcg ethinyl estradiol with levonorgestrel versus non-use: 2.2 (95% CI 1.3-3.6) | |
30 mcg ethinyl estradiol with levonorgestrel versus 20 mcg ethinyl estradiol with levonorgestrel: 1.1 (95% CI 0.7-1.7) | ||
50 mcg ethinyl estradiol with levonorgestrel versus 20 mcg ethinyl estradiol with levonorgestrel: 2.3 (95% CI 1.3-4.2)[2,3] | ||
Thrombophilias | Factor V Leiden: 2.6 no OC, 64.7 first/second generation, 29.6 third generation | |
Other heritable thrombophilia: 2.6 no OC, 63.3 first/second generation; 52.5 third generation[4] |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟